HEALTH● LOWSep 2 · Sep 2, 2026, 4:15 AM
Telix Completes Enrollment in Phase 3 BiPASS Study , Aligns with FDA on NDA Pathway
singaporestar.com · Singapore · north america
Telix has finished enrolling participants for its Phase 3 BiPASS study and has coordinated with the FDA regarding the New Drug Application process, marking progress in drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More from Singapore
WORLD2h agoSingapore weighs legal action against companies over worsening transboundary hazeSouth China Morning PostDISASTER3h agoIndonesia's skies turn apocalyptic orange as smoke blankets SingaporeEuroNews [en]POLITICS5h agoCanada, Singapore reaffirm China trade ties amid global push for self-sufficiencySouth China Morning PostBUSINESS7h agoTamil Nadu CM Vijay holds talks with Singapore Deputy PM on economic ties, investmentsThe Hindu
More in Health
HEALTH41m agoNCDs fastest-growing disease burden in Nigeria — OfficialPremium TimesHEALTH55m agoFG ‘revitalises’ 4,434 PHCs, expands access to quality healthcare servicesPremium TimesHEALTH1h agoProbiotic cuts risk of respiratory infections in formula-fed babiesNew ScientistHEALTH1h agoCleft lip and palate and other craniofacial surgery for kids isn’t cosmetic, it’s lifesavingThe Hill